Shih-Ming Kuo

Dr. Shih-Ming Kuo

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
YCYUNG-SHENG CHENG
YUNG-SHENG CHENG
CCChi-Hsiang Chung
Chi-Hsiang Chung
SKShih-Ming Kuo
Shih-Ming Kuo
CLChih-Ping Lin
Chih-Ping Lin
TWTsu-Hsuan Weng
Tsu-Hsuan Weng
PLPeng-Fei Li
Peng-Fei Li
Background: Studies have suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may modulate asthma-related immune pathways, but evidence directly linking the use of GLP-1 RAs to asthma onset remains limited. Objectives: We aimed to evaluate whether the use of GLP-1 RAs in patients with type 2 diabetes mellitus (T2DM) is associated with a reduced risk and severity of asthma development. Design: This retrospective cohort study was designed to evaluate asthma onset and severity in patients with T2DM treated with GLP-1 RAs, using data from the National Health Insurance Database (2011–2015). Methods: Asthma onset and severity were evaluated in 1345 patients with T2DM treated with GLP-1 RAs from a cohort of 1,936,512 individuals, excluding those with pre-existing asthma. Asthma risk was assessed across four severity levels. Results: The study demonstrated a mean follow-up duration of 2.92 ± 1.82 years. Notably, treatment with GLP-1 RAs significantly reduced asthma risk compared with the non-GLP-1 RA group, as indicated by an adjusted hazard ratio (HR) of 0.67 (95% confidence interval (CI), 0.45–0.76), suggesting a consistent class effect. A protective trend was observed across various severity levels of asthma. The HRs for the GLP-1 RA group compared with the non-GLP-1 RA group for cases with no acute exacerbations (No-AE), acute exacerbations (AE), and status asthmaticus (Status) were 0.55 (95% CI, 0.37–0.62), 0.59 (95% CI, 0.39–0.66), and 0.83 (95% CI, 0.56–0.93), respectively. However, in cases requiring endotracheal intubation, the HR was 0.96 (95% CI, 0.65–1.09). Conclusion: Our study highlights a consistent effect of GLP-1 RAs in reducing asthma risk and severity, except in cases requiring endotracheal intubation, suggesting that GLP-1 RAs may contribute to reducing asthma incidence and severity in patients with T2DM.

3 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
YCYUNG-SHENG CHENG
YUNG-SHENG CHENG
DPDee Pei
Dee Pei
TCTa-Wei Chu
Ta-Wei Chu
SKShih-Ming Kuo
Shih-Ming Kuo
Yao-Jen LiangYao-Jen Liang
Yao-Jen Liang
Background: Type 2 diabetes (T2D) and insulin resistance (IR) are major global health challenges. Volatile organic compounds (VOCs) in exhaled breath offer a non-invasive window into metabolic dysregulation. This study aimed to predict HOMA-IR using machine learning (ML) by integrating biochemical markers and VOC profiles in a male cohort. Methods: This cross-sectional study included 1258 male participants from the Taiwan MJ cohort. Four ML algorithms (Elastic Net, MARS, Random Forest, and XGBoost) were trained to predict HOMA-IR. Model performance was evaluated using R2, RMSE, and MAE. SHAP analysis was used to interpret feature contributions. Results: Ensemble tree-based approaches (Random Forest and XGBoost) demonstrated better predictive performance than Elastic Net and MARS. Random Forest achieved the highest predictive performance on the test set (R2 = 0.323). SHAP analysis identified BMI (mean |SHAP| = 1.326) as the strongest predictor, followed by TG (1.005) and HDL-C (0.445). Notably, specific breath VOCs, including methanol and formic acid, ranked among the top 20 predictors, capturing distinct aspects of metabolic dysregulation orthogonal to standard blood tests. Conclusions: Integrating VOC profiles with clinical markers provides acceptable predictive performance for IR in men. While traditional metabolic markers dominate the prediction, specific VOCs capture distinct metabolic information, highlighting the potential of breath analysis as a complementary early screening tool.